Olstein Capital Management L.P. Has $2.82 Million Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Olstein Capital Management L.P. grew its position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 37.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 155,000 shares of the life sciences company's stock after acquiring an additional 42,000 shares during the period. Olstein Capital Management L.P. owned about 0.20% of Integra LifeSciences worth $2,816,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Principal Financial Group Inc. increased its holdings in Integra LifeSciences by 18.7% in the third quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company's stock valued at $7,294,000 after buying an additional 63,266 shares in the last quarter. New York State Teachers Retirement System boosted its position in shares of Integra LifeSciences by 3.0% in the 3rd quarter. New York State Teachers Retirement System now owns 90,098 shares of the life sciences company's stock worth $1,637,000 after buying an additional 2,616 shares in the last quarter. State of Alaska Department of Revenue grew its stake in Integra LifeSciences by 144.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 131,751 shares of the life sciences company's stock valued at $2,393,000 after acquiring an additional 77,825 shares during the last quarter. Tandem Capital Management Corp ADV increased its holdings in Integra LifeSciences by 43.4% during the 3rd quarter. Tandem Capital Management Corp ADV now owns 38,851 shares of the life sciences company's stock valued at $706,000 after acquiring an additional 11,765 shares in the last quarter. Finally, Northwest Investment Counselors LLC purchased a new position in shares of Integra LifeSciences during the 3rd quarter worth approximately $73,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently weighed in on IART shares. Truist Financial cut their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a research note on Monday, October 14th. Morgan Stanley raised their price objective on Integra LifeSciences from $24.00 to $27.00 and gave the company an "underweight" rating in a research report on Monday, July 15th. BTIG Research raised shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a research note on Monday, October 7th. JMP Securities lowered their price objective on Integra LifeSciences from $40.00 to $35.00 and set a "market outperform" rating for the company in a research note on Tuesday, July 30th. Finally, Citigroup upped their target price on Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a research report on Tuesday. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $27.25.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART traded down $1.19 during trading on Thursday, reaching $25.51. The stock had a trading volume of 1,019,919 shares, compared to its average volume of 1,104,465. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.10 and a current ratio of 3.39. The stock has a market cap of $1.98 billion, a PE ratio of -289.67, a P/E/G ratio of 0.82 and a beta of 1.08. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $45.42. The firm's 50 day moving average price is $18.90 and its two-hundred day moving average price is $24.40.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.25%. The firm had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. During the same quarter in the previous year, the firm earned $0.76 earnings per share. The firm's revenue for the quarter was down .4% compared to the same quarter last year. On average, research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.